- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03693092
LAmbre™ Left Atrial Appendage Closure System Follow-Up Study
LAmbre™ Left Atrial Appendage Closure System Post-Market 2-5 Years Follow-Up Study
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
All subjects who completed 1-year follow-up of the LAmbreTM LAA system registration trial will be conducted 2 years, 3 years, 4 years and 5 years follow-up by the telephone call.
During the follow-up, the investigator or his/her designee will use a standardized form to record the occurrence of the subject's safety events and validity endpoint by telephone,and complete the safety and efficacy summary report. The endpoints of the study included compound events, MACCE events, stroke, haemorrhage and other events.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
-
Chengdu, Cina
- West China Hospital, Sichuan University
-
-
Beijing
-
Beijing, Beijing, Cina
- Beijing Chaoyang Hospital, Capital Medical University
-
Beijing, Beijing, Cina
- Fuwai Hospital Chinese Academy of Medical Science
-
-
Heilongjiang
-
Harbin, Heilongjiang, Cina
- The 2nd Affiliated Hospital of Harbin Medical University
-
-
Hubei
-
Wuhan, Hubei, Cina
- Wuhan Asia Heart Hospital
-
Wuhan, Hubei, Cina
- People's Hospital of Wuhan University
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina
- Jiangsu Province Hospital
-
-
Liaoning
-
Shenyang, Liaoning, Cina
- The General Hospital Of Shenyang Military Region
-
-
Shandong
-
Dalian, Shandong, Cina
- The First Affiliated Hospital of Dalian Medical University
-
-
Shanghai
-
Shanghai, Shanghai, Cina
- Shanghai Tenth People's Hospital
-
Shanghai, Shanghai, Cina
- Xinhua Hospital Affiliated Shanghai Jiaotong University School of Medicine
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Patients who participated in the LAmbreTM Safety and Efficacy Study and completed the 1-year follow-up.
The inclusion criteria of LAmbreTM Safety and Efficacy Study:
- Age>=18, CHADS2 score>=1
- Patients cannot be treated long-term with Warfarin
- Eligible for clopidogrel and aspirin
- Provide written informed consent and agree to comply with the required follow-ups
Exclusion Criteria:
- Exclusion criteria: Patients who did not participate in the LAmbreTM Safety and Efficacy Study or did not complete 1-year follow-up LAmbreTM Safety and Efficacy Study.
The exclusion criteria of LAmbreTM Safety and Efficacy Study:
- Need to take Warfarin
- Presence of rheumatic, degenerative or congenital valvular heart diseases
- Early stage or paroxysmal atrial fibrillation
- Symptomatic patients with carotid artery disease (such as carotid stenosis>=50%)
- Heart failure NYHA grade IV
- Recent 30 days stroke or TIA
- Presence of active sepsis or endocarditis
- Cardiac tumours or other malignancy with estimated life expectancy <2 years
- Abnormal blood test; renal dysfunction
- LAA removed or heart implant patients
- Patients have planned electrophysiological ablation or cardioversion 30 days post implantation of the LAmbre system
- Patients have a history of mechanical prosthesis operation
- Patients who are pregnant, or desire to be pregnant during the during the study
- Participation in other trials
- A known allergy to nitinol
- Patients will not be able to complete the trial
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The incidence of compound event
Lasso di tempo: 5 years after the surgery
|
The compound event including death, systemic embolization, complications related to the device and requiring treatment (cardiac embolism, embolization, stroke, hemorrhage, death).
|
5 years after the surgery
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The incidence of MACCE events
Lasso di tempo: 2,3,4,5 years postoperative follow-up.
|
The MACCE events including death (All cause death, All-cause death includes cardiac death, non-cardiac death and unexplained death), stroke, cardiac tamponade, and renal failure.
|
2,3,4,5 years postoperative follow-up.
|
Ischemic stroke rate
Lasso di tempo: 2,3,4,5 years postoperative follow-up
|
Ischemic stroke is a neurological deficit caused by transient ischemic attack, cerebral thrombosis or cerebral embolism.
|
2,3,4,5 years postoperative follow-up
|
The rate of stroke
Lasso di tempo: 2,3,4,5 years postoperative follow-up
|
Stroke is deviated into ischemic, hemorrhagic or undetermined stroke, and transient ischemic attacks (TIA).
|
2,3,4,5 years postoperative follow-up
|
The event of bleeding
Lasso di tempo: 2,3,4,5 years postoperative follow-up
|
Intracranial or alimentary canal, or any bleeding that requires transfusion of 2 units of red blood cell suspension.
|
2,3,4,5 years postoperative follow-up
|
Cardiac events
Lasso di tempo: 2,3,4,5 years postoperative follow-up
|
Non-fatal myocardial infarction, arrhythmia, cardiac tamponade, cardiogenic shock, endocarditis.
|
2,3,4,5 years postoperative follow-up
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Congxin Huang, People's Hospital of Wuhan University
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- LAA 2-5ys FU
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .